DrugSuccess.Ai™ by ThinkBio.Ai® is an AI-driven platform that forecasts therapeutic success prior to clinical investment. It integrates disease models, target genetics, multi‑omics, preclinical evidence, and curated public data. Using advanced AI and statistical models, DrugSuccess.Ai™ calculates a Drug Success Score to predict therapeutic progression from preclinical to approval. Empowering biopharma with data-driven insights, it reduces R&D risk and aids strategic target selection.
DrugSuccess.Ai™ enables biopharma teams and investors to prioritize therapies with the highest likelihood of success. By integrating disease models, target-associated genetic, multi-omics, multimodal preclinical data, and curated literature, it generates a Drug Success Score. This allows early assessment of translational risks, optimizes resource allocation, and supports data-driven portfolio decisions, leveraging insights from past successes and failures to guide smarter, faster, and more confident drug development strategies.
DrugSuccess.Ai™’s unified framework integrates multi‑omics data, literature, and preclinical results to build knowledge graphs linking targets, diseases, and mechanisms. Advanced predictive models, trained on historic successes and failures, compute the Drug Success Score, estimating a therapy’s chance of progression through preclinical, clinical, and regulatory phases. Finally, decision‑makers receive actionable insights via visual dashboards and summaries.
Combines disease models, target-associated genetic information, multi-omics, and preclinical study data to create a comprehensive view of drug–target interactions.
Incorporates peer-reviewed studies and public datasets to provide evidence-backed insights into drug–target–disease relationships and past development outcomes.
Generates a quantitative, explainable score that estimates the probability of a therapy successfully advancing from preclinical stages through clinical trials to regulatory approval.
Visualizes complex relationships between targets, diseases, and therapies, enabling teams to quickly identify patterns and risk factors that could impact therapeutic success.
Includes historical successes and failures for similar targets or modalities, supporting strategic decision-making and prioritization of high-value assets.
Helps investors evaluate portfolio companies and therapeutic pipelines by providing data-driven insights into likelihood of success and potential return on investment.
Would you like us to get in touch with you? Fill up the form & we will reach out to you